Emerging data suggest Retatrutide , a dual activator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may provide a significant advancement for body management . Initial clinical trials have shown considerable reductions in visceral fat , possibly outperforming current body composition treatments. Nevertheless ,